SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001206774-09-001498
Filing Date
2009-08-04
Accepted
2009-08-04 07:30:34
Documents
7
Period of Report
2009-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT regeneron_10q.htm 10-Q 719523
2 IL-1 ANTIBODY AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG, NOVARTIS exhibit10-1.htm EX-10.1 138569
3 GRAPHIC regeneron_8k8x5x1.jpg GRAPHIC 3334
4 TRAP-2 TERMINATION AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG, NOVARTIS exhibit10-2.htm EX-10.2 124730
5 CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE exhibit31-1.htm EX-31.1 8498
6 CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE exhibit31-2.htm EX-31.2 8898
7 CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350. exhibit32.htm EX-32 3273
  Complete submission text file 0001206774-09-001498.txt   1009546
Mailing Address
Business Address 777 OLD SAW MILL RIVER RD TARRYTOWN NY 10591-6707 9143477000
REGENERON PHARMACEUTICALS INC (Filer) CIK: 0000872589 (see all company filings)

IRS No.: 133444607 | State of Incorp.: NY | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-19034 | Film No.: 09981651
SIC: 2834 Pharmaceutical Preparations